GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...

Prostate cancer screening for men over 70 is complex, with current recommendations against routine PSA testing due to slow ...

A globally-renowned prostate cancer surgeon shares the latest advancements in the field and stresses the importance of early ...

The National Institute for Health and Care Excellence (NICE) has recommended darolutamide in combination with androgen ...

NICE recommendation of darolutamide plus hormone therapy for metastatic prostate cancer offers around 6000 patients in ...

The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.

Adding the drug enzalutamide to standard hormone therapy reduced deaths by more than 40% in men with recurrent prostate ...

NICE recommends Bayer’s Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option for patients with hormone-sensitive metastatic prostate cancer Nubeqa® (darolutamide) plus ...

Discover a study on PARP inhibitors in prostate cancer, revealing survival benefits for patients with BRCA1/2 alterations.

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

Patients with metastatic hormone-sensitive prostate cancer (mHSPC) lived significantly longer without disease progression ...

When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...